close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ITM Isotope Technologies Munich SE

< Previous 1 2 Next >
News headline image
ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Participate in Upcoming Investor Conferences
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Appoints Annette Breunig as Chief People Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
Barbara Weber, M.D., Elected to ITM Supervisory Board
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Appoints Dr. Celine Wilke as Chief Medical Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Announces Updates to Commercial Leadership
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present at Raymond James Private Biotech Symposium
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM to Participate in Upcoming Investor Conferences
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today